Lixumistat (IM156)
Pancreatic Cancer
Phase 1bActive
Key Facts
About ImmunoMet Therapeutics
ImmunoMet Therapeutics is a private, clinical-stage biotech focused on targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies. The company's core platform involves inhibiting oxidative phosphorylation (OxPhos) via protein complex 1 (PC1) inhibitors, with its lead candidate, lixumistat, currently in Phase 1b trials for pancreatic cancer. Founded as a spin-off from HanAll Biopharma, ImmunoMet has raised $39 million to date and is advancing a library of biguanide compounds. Its interim leadership and scientific advisory boards bring decades of pharmaceutical R&D experience to the venture.
View full company profileOther Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| HBM9027 | Harbour BioMed | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| AHPBA IRE Registry | AngioDynamics | Post-Market Registry |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Pritumumab (PTB) | Nascent Biotech | Phase II (Planned) |
| Pancreatic Cancer Test | Mosaique Diagnostic | Development |
| Iontophoretic System | Continuity Biosciences | Pre-clinical |
| Electron IORT | Intraop Medical | Approved |